An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia

American Journal of Managed Care

Volumn 12, Issue SUPPL. 4, 2006, Pages

  Black, Libby ^b   Naslund, Michael James ^b   Gilbert Jr , Thomas O ^b   Davis, E Anne ^b   Ollendorf, Daniel A ^a  

^a PharMetrics Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGING; ARTICLE; COHORT ANALYSIS; CONSULTATION; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MINIMALLY INVASIVE SURGERY; PATIENT MONITORING; PHARMACY; POSTOPERATIVE COMPLICATION; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROSTATECTOMY; RETREATMENT; TRANSURETHRAL RESECTION; TREATMENT INDICATION; UNIVARIATE ANALYSIS;

AGED; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC HYPERPLASIA; UNITED STATES;

EID: 33645469500     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan, ED Jr, Wein AJ, eds. Campbell's Urology. Philadelphia, Pa: WB Saunders;2002:1297-1330.
2. Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl. 1996;6:67-73.
3. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:495-507.
4. ADA Practice Guidelines Committee. ADA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170:530-547.
5. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557-563.
6. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999;54:670-678.
7. Goluboff ET, Olsson CA. Urologists on a tightrope: coping with a changing economy. J Urol. 1994;151:1-4.
8. US Census Population Projections. Available at: http://www.census.gov/ population/projections/nation/. Accessed September 15, 2003.
9. Blomqvist P, Ekbom A, Carlsson P, Ahlstrand C, Johansson JE. Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs. Urology. 1997;50:214-219.
10. Suaid HJ, Goncalves MA, Rodrigues AA Jr, Cunha JP, Cologna AJ, Martins AC. Estimated costs of treatment of benign prostate hyperplasia in Brazil. Int Braz J Urol. 2003;29:234-237.
11. O'Leary MP. Evaluating symptoms and functional status in benign prostate hyperplasia. Br J Urol. 1995; 76(suppl 1):25-28.
12. Roehrborn CG, Bartsch G, Kirby R, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology. 2001;58:642-650.
13. US Census Population Projections. Available at: http://www.census.gov/ popest/estimates.php. Accessed October 15, 2003.
14. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology. 2003;62(3 suppl 1):24-33.